Dimethyl fumarate, an activator of the Nrf2 pathway, is a Food and Drug Administration- and European Medicines Agency-approved first-line oral therapy for patients with relapsing forms of multiple sclerosis (MS) [12]. This evidence concerns the gene NFE2L2 and multiple sclerosis.